Novavax Valuation

NVAX Stock  USD 7.31  0.18  2.52%   
Tangible Asset Value is likely to rise to about 2.3 B in 2023, whereas Free Cash Flow is likely to drop (522.3 M) in 2023. Novavax secures a last-minute Real Value of $10.61 per share. The latest price of the firm is $7.31. At this time, the firm appears to be undervalued. Our model forecasts the value of Novavax from analyzing the firm fundamentals such as Current Valuation of 374.31 M, profit margin of (0.37) %, and Return On Equity of -8.98 as well as examining its technical indicators and Probability Of Bankruptcy. In general, we recommend acquiring undervalued stocks and dropping overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Enterprise Value
374.3 M
Current Deferred Revenue
370.1 M
Net Debt
-787.1 M
Accounts Payable
216.5 M
Novavax Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Novavax's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Today 7.31
Please note that Novavax's price fluctuation is slightly risky at this time. Calculation of the real value of Novavax is based on 3 months time horizon. Increasing Novavax's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Novavax is useful when determining the fair value of the Novavax stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Novavax. Since Novavax is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novavax Stock. However, Novavax's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Real Value
Estimating the potential upside or downside of Novavax helps investors to forecast how Novavax stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novavax more accurately as focusing exclusively on Novavax's fundamentals will not take into account other important factors:
Estimates (6)
LowNext ValueHigh
6 Analysts
LowTarget PriceHigh
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Novavax's intrinsic value based on its ongoing forecasts of Novavax's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Novavax's closest peers. When choosing an evaluation method for Novavax, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

Novavax Investments

195.61 Million

Novavax Valuation Drivers Correlation

Many accounts on the financial statements of Novavax are highly interrelated and sometimes correlated. Consequently, when conducting Novavax's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Novavax
Click cells to compare fundamentals

Novavax Valuation Trend

Knowing Novavax's actual value is paramount for traders to make sound investment determinations. Novavax's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Novavax's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Novavax's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

Novavax Market Cap

Novavax is considered to be number one stock in market capitalization category among related companies. Market capitalization of Health Care industry is now estimated at about 86.01 Billion. Novavax maintains roughly 719.45 Million in market capitalization contributing less than 1% to equities under Health Care industry.
Capitalization  Total debt  Workforce  Valuation  Revenue

Novavax Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Novavax's current stock value. Our valuation model uses many indicators to compare Novavax value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novavax competition to find correlations between indicators driving Novavax's intrinsic value. More Info.
Novavax is considered to be number one stock in net asset category among related companies. It is considered to be number one stock in price to sales category among related companies . The ratio of Net Asset to Price to Sales for Novavax is about  4,693,846,633 . Price to Sales Ratio is likely to rise to 0.42 in 2023. Comparative valuation analysis is a catch-all model that can be used if you cannot value Novavax by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Novavax's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novavax's earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Novavax's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Novavax and how it compares across the competition.

About Novavax Valuation

The stock valuation mechanism determines the current worth of Novavax on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Novavax. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Novavax based exclusively on its fundamental and basic technical indicators. By analyzing Novavax's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Novavax's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Novavax. We calculate exposure to Novavax's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Novavax's related companies.
Last ReportedProjected for 2023
Gross Profit1.1 B1.2 B
Profit Margin(0.33)(0.36)

Novavax Quarterly Enterprise Value

205.02 Million

8 Steps to conduct Novavax's Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Novavax's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Novavax's valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Novavax's financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Novavax's revenue streams: Identify Novavax's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Novavax's industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Novavax's growth potential: Evaluate Novavax's management, business model, and growth potential.
  • Determine Novavax's financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Novavax's estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Novavax Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Novavax does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding78.2 M
Forward Price Earnings0.5781

Novavax Current Valuation Indicators

Valuation refers to the process of determining the present value of Novavax and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Novavax we look at many different elements of the entity such as Novavax's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Novavax's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Novavax's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Novavax, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Novavax's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Novavax's worth.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide. Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Novavax Stock analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Fundamental Analysis
View fundamental data based on most recent published financial statements
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
Return On Equity
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.